sign130
sign130
sign130
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
12 • Implementing the guideline<br />
y the proportion of patients with cognitive impairment after TBI that receives interventions for cognitive<br />
impairments as part of a comprehensive-holistic programme delivered by a multidisciplinary team<br />
y the proportion of patients with memory impairment after TBI that receives training in the use of<br />
compensatory memory strategies<br />
y the proportion of patients with attention impairment after TBI that receives training in the use of strategies<br />
to manage attention problems in personally relevant situations<br />
y the proportion of patients with executive functioning impairments after TBI that receives training in the<br />
use of metacognitive strategies focused on managing difficulties with planning, problem solving and<br />
goal management in personally relevant situations.<br />
12.4 ADDITIoNAl ADVICE To NHSSCoTlAND fRoM HEAlTHCARE IMPRoVEMENT SCoTlAND<br />
AND THE SCoTTISH MEDICINES CoNSoRTIuM<br />
In October 2011, the Scottish Medicines Consortium (SMC) advised that botulinum toxin type A (xeomin®)<br />
is accepted for use within NHS Scotland for adults with post-stroke spasticity of the upper limb presenting<br />
with flexed wrist and clenched fist.<br />
In March 2011, SMC advised that botulinum toxin type A (Botox®) is accepted for use within NHSScotland for<br />
adults with focal spasticity, including the treatment of wrist and hand disability due to upper limb spasticity<br />
associated with stroke.<br />
In january 2013, SMC advised that clostridium botulinum type A toxin-haemagglutinin complex (Dysport®)<br />
is accepted for use within NHSScotland for focal spasticity associated with stroke, including the treatment<br />
of arm symptoms associated with focal spasticity in conjunction with physiotherapy.<br />
| 49